



(51) International Patent Classification:

C07J 9/00 (2006.01) A61K 31/575 (2006.01)
C07J 31/00 (2006.01) A61P 1/16 (2006.01)
C07J 41/00 (2006.01)

(72) Inventor; and

(75) Inventor/Applicant (for US only): PELLICCIARI,
Roberto [IT/IT]; Via Ulisse Rocchi, 60, I-06123 Perugia
(IT).

(21) International Application Number:

PCT/US2009/065188

(74) Agents: ELRIFI, Ivor, R. et al.; Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo PC, One Financial Center,
Boston, MA 02111 (US).

(22) International Filing Date:

19 November 2009 (19.11.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08169462.2 19 November 2008 (19.11.2008) EP

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US EP 08169462.2 (CIP)
Filed on 19 November 2008 (19.11.2008)
US 081694622 (CON)
Filed on 19 November 2008 (19.11.2008)

(71) Applicant (for all designated States except US): INTER-
CEPT PHARMACEUTICALS, INC. [US/US]; 18 Des-
brosses Street, New York, NY 10013 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: TGR5 MODULATORS AND METHOD OF USE THEREOF





Fig. 1

(57) Abstract: The invention relates to compounds of Formula A: (A) or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.



MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, **Published:**
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — *with international search report (Art. 21(3))*
ML, MR, NE, SN, TD, TG).